A.D.A.
A.D.A. – Advanced Drug Administration is an innovative startup dedicated to developing advanced inhalation therapies for interstitial lung diseases, leveraging nanomedicine-based technology to provide targeted, effective, and patient-centric treatments. Their mission focuses on addressing the urgent need for better therapies for rare lung diseases through innovative drug delivery platforms that maximize efficacy and minimize toxicity.
Industries
Products
Inhaled TGF‑β inhibitor formulation (antifibrotic carrier)
An inhaled formulation embedding a TGF‑β pathway inhibitor into an amphiphilic nanoparticle carrier that also exerts intrinsic antifibrotic effects; designed for local pulmonary administration to modulate fibrotic signalling.
Mycophenolic‑acid‑derived self‑assembling nanoparticle immunomodulator
A self‑assembling nanoparticle system composed of a mycophenolic acid prodrug designed for inhalation to selectively inhibit lymphocyte proliferation and modulate pulmonary immune activity; formulation increases aqueous solubility and mucus penetration compared with traditional MPA formulations.
Combination nanoparticle therapy (antifibrotic + immunomodulator)
A combination approach where an antifibrotic small molecule is encapsulated into the self‑assembling immunomodulatory nanoparticles to address both fibrotic mechanisms and immune hyperactivation in the lung.
Inhaled TGF‑β inhibitor formulation (antifibrotic carrier)
An inhaled formulation embedding a TGF‑β pathway inhibitor into an amphiphilic nanoparticle carrier that also exerts intrinsic antifibrotic effects; designed for local pulmonary administration to modulate fibrotic signalling.
Mycophenolic‑acid‑derived self‑assembling nanoparticle immunomodulator
A self‑assembling nanoparticle system composed of a mycophenolic acid prodrug designed for inhalation to selectively inhibit lymphocyte proliferation and modulate pulmonary immune activity; formulation increases aqueous solubility and mucus penetration compared with traditional MPA formulations.
Combination nanoparticle therapy (antifibrotic + immunomodulator)
A combination approach where an antifibrotic small molecule is encapsulated into the self‑assembling immunomodulatory nanoparticles to address both fibrotic mechanisms and immune hyperactivation in the lung.
Expertise Areas
- Inhaled nanomedicine development
- Interstitial lung disease therapeutics (IPF, CTD‑ILD, SSc‑ILD)
- Nanoparticle formulation and prodrug design
- Preclinical modeling and in vivo imaging
Key Technologies
- Self‑assembling drug‑only nanoparticles
- Amphiphilic carrier nanoparticle design
- Pulmonary aerosol/inhalation formulations
- Mucus‑penetrating formulation technologies